12-Month outcomes of transcatheter tricuspid valve repair with the PASCAL system for severe tricuspid regurgitation

Mitsunobu Kitamura, Neil P. Fam, Daniel Braun, Tobias Ruf, Atsushi Sugiura, Akhil Narang, Kim A. Connelly, Edwin Ho, Michael Nabauer, Jörg Hausleiter, Marcel Weber, Georg Nickenig, Charles J. Davidson, Holger Thiele, Ralph Stephan von Bardeleben, Philipp Lurz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Objectives: We investigated the durability of tricuspid regurgitation (TR) reduction and the clinical outcomes through 12 months after transcatheter tricuspid valve repair (TTVr) with the PASCAL Transcatheter Valve Repair System. Background: TTVr has rapidly developed and demonstrated favorable acute outcomes, but longer follow-up data are needed. Methods: Overall, 30 patients (age 77 ± 6 years; 57% female) received PASCAL implantation from September 2017 to May 2019 and completed a clinical follow-up at 12 months. Results: The TR etiology was functional in 25 patients (83%), degenerative in three (10%), and mixed in two (7%). All patients had TR severe or greater (massive or torrential in 80%) and heart failure symptoms (90% in NYHA III or IV) under optimal medical treatment. Single-leaflet device attachment occurred in two patients. Moderate or less TR was achieved in 23/28 patients (82%) at 30 days, which was sustained at 12 months (86%). Two patients underwent repeat TTVr due to residual torrential TR (day 173) and recurrence of severe TR (day 280), respectively. One-year survival rate was 93%; 6 patients required rehospitalization due to acute heart failure. NYHA functional class I or II was achieved in 90% and 6-minute walk distance improved from 275 ± 122 m at baseline to 347 ± 112 m at 12-month (+72 ± 82 m, p <.01). There was no stroke, endocarditis, or device embolization during the follow-up. Conclusions: Twelve-month outcomes from this multicenter compassionate use experience with the PASCAL System demonstrated high procedural success, acceptable safety, and significant clinical improvement.

Original languageEnglish (US)
Pages (from-to)1281-1289
Number of pages9
JournalCatheterization and Cardiovascular Interventions
Issue number6
StatePublished - May 1 2021


  • 12-month outcomes
  • right-sided heart failure
  • severe tricuspid regurgitation
  • transcatheter tricuspid valve intervention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of '12-Month outcomes of transcatheter tricuspid valve repair with the PASCAL system for severe tricuspid regurgitation'. Together they form a unique fingerprint.

Cite this